Tirzepatide is an injected GIP and GLP-1 receptor agonist taken once a week, marketed as Zepbound for weight and sleep apnea and as Mounjaro for type 2 diabetes.
Weight loss or diabetes: the label decides coverage
For Sacramento Medi-Cal members, the reason for the prescription now matters. Medi-Cal no longer pays for GLP-1s used for adult weight loss, but uses for other conditions can be covered if medically necessary [2]. Tirzepatide is sold under two labels: Mounjaro for type 2 diabetes in adults and children 10 and older [5], and Zepbound for chronic weight management and obstructive sleep apnea with obesity [6]. In Sacramento, 11.2% of adults have diagnosed diabetes [3].
Sponsored placement: open.
One local practice can be featured here. This is a paid, labeled placement and never an endorsement.
Feature your practice in Sacramento, from $300 a month.
Sacramento practices may buy the labeled slot above. It is an ad, and it has no say over what we write.
Cash prices a Sacramento patient sees
| What you buy | Monthly cost | Notes |
|---|---|---|
| Zepbound 2.5 mg, first four weeks | $299 [1] | Pen or vial, 28-day supply |
| Zepbound 5 mg | $399 [1] | Same price either form |
| Zepbound 7.5 mg to 15 mg | $449 [1] | Holds only with a refill within 45 days |
| Mounjaro, diabetes brand, list | $1,112.16 per 28 days [7] | Four pens; insurance usually applies |
Let that refill slip past day 45 and LillyDirect bills its regular rate: $499 for 7.5 mg, $699 for 10, 12.5 or 15 mg [1]. A calendar reminder is cheap insurance.
Medicare: the KwikPen detail
With 14.2% of Sacramento residents 65 or older [4], Medicare questions come up often. The Medicare GLP-1 Bridge covers the Zepbound KwikPen, but not Zepbound vials or single-dose pens, for eligible Part D enrollees at a $50 monthly copay through December 31, 2027 [8] [9]. Eligibility depends on BMI plus certain conditions, such as a BMI of 35 or higher, or 27 or higher with prediabetes or a prior heart attack or stroke [9]. Details: Medicare and GLP-1s.
Compounded and research-use tirzepatide
Compounded tirzepatide is not FDA-approved, and FDA does not review it for safety, effectiveness or quality [10]. Products labeled for research use only are not meant for people at all, and FDA has warned companies that sell research-use GLP-1s [10]. See compounded tirzepatide and research-use-only GLP-1s. Check California prescribers with the Medical Board of California [11].
Other West Coast pages: Los Angeles, San Diego, Las Vegas and, farther north, Seattle. Background: tirzepatide guide.
Label cautions
Before the first Sacramento dose
Anyone with MEN 2, or with medullary thyroid carcinoma in themselves or the family, should not take tirzepatide; that is the boxed warning. Pain in the belly that is severe and keeps going needs a doctor quickly. Combining it with a sulfonylurea or insulin can drop blood sugar too low: in a diabetes trial where people also took a sulfonylurea, 10.3% on tirzepatide had low blood sugar [12]. Pregnancy means stopping. A serious allergic reaction is a 911 call.
Questions people ask
What will a Sacramento cash buyer pay for Zepbound?
LillyDirect charged $299 for the 2.5 mg starter, $399 for 5 mg, and $449 for 7.5 to 15 mg with refills inside 45 days, as of Oct 17, 2026 [1].
Can a Sacramento Medi-Cal member still get Mounjaro for diabetes?
Which Zepbound form works with Medicare's Bridge?
Only the KwikPen. The Medicare GLP-1 Bridge leaves out Zepbound vials and single-dose pens [8].
What share of Sacramento adults have diabetes?
CDC PLACES estimates 11.2% of adults in the city of Sacramento had diagnosed diabetes in 2023 [3].
How many Sacramento residents are 65 or older?
The Census Bureau puts the share at 14.2% of city residents [4].
What did long-term tirzepatide use show in SURMOUNT-4?
Those who stayed on tirzepatide for 88 weeks averaged a 25.3% weight reduction, against 9.9% for people switched to placebo after week 36 [13].
Sources
13 cited
- Zepbound self-pay pricing. Eli Lilly and Company (LillyDirect), accessed 2026-10-17.
- California Medicaid ends coverage of GLP-1 weight loss drugs. KFF Health News, Jan 9, 2026.
- PLACES place data: Sacramento, CA. CDC PLACES (2025 release, BRFSS 2023), 2023 data, 2025 release.
- QuickFacts: Sacramento city, California. U.S. Census Bureau, QuickFacts, V2025; ACS 2020-2024.
- Mounjaro label. DailyMed, NLM, Aug 2026.
- Zepbound label. DailyMed, NLM, Aug 2026.
- Mounjaro FAQ: pricing. Eli Lilly and Company, accessed 2026-10-17.
- Medicare GLP-1 Bridge: information for pharmacies. Centers for Medicare & Medicaid Services, accessed 2026-10-17.
- Weight loss drugs coverage. Medicare.gov (CMS), accessed 2026-10-17.
- FDA's concerns with unapproved GLP-1 drugs used for weight loss. US Food and Drug Administration, Oct 1, 2026.
- Medical Board of California. Medical Board of California, accessed 2026-10-17.
- Zepbound prescribing information. US FDA (accessdata.fda.gov), Apr 2026.
- Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA (PubMed), Jan 1, 2024.
This page is general information, not medical advice. Talk with a licensed clinician about your own care.